The Technical Analyst
Cortexyme, Inc. [CRTX]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology
Cortexyme, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.63% $1.950
/ 1 aug 2022 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 70.45 mill |
| EPS: | -2.96 |
| P/E: | -0.658 |
| Earnings Date: | Aug 08, 2022 |
| SharesOutstanding: | 36.13 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2022-09-30 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.658 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.658 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.708 - 2.19 ( +/- 12.41%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-29 | Monohon Ted | Buy | 250 000 | Stock Option (right to buy) |
| 2022-06-09 | Bray June | Buy | 54 000 | Stock Option (right to buy) |
| 2022-06-09 | Bray June | Buy | 0 | |
| 2022-06-08 | Senner Christopher J. | Buy | 27 000 | Stock Option (right to buy) |
| 2022-06-08 | Ryan Una S | Buy | 27 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 97.49 |
| Last 94 transactions |
| Buy: 5 069 399 | Sell: 426 503 |
Forecast:
01:40 - $1.455
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.950 (2.63% ) |
| Volume | 0.272 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CRTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CRTX
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Latest Press Releases
2021-10-26 16:01:00 - Press Release
Cortexyme Reports Gain Trial Data Demonstrated Relationship Between Reduction Of P. Gingivalis Infection And Slowing Of Alzheimer’s Disease Progression
South san francisco, calif.--(business wire)--cortexyme, inc. (nasdaq: crtx) today reported top-line results from its phase 2/3 gain trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (cor388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium porphyromonas gingivalis (p. gingivalis). the 643-participant study in mild to moderate patients with alzheimer’s disease did not meet statistical significance in its co-primary cognitive and functional endpoints as measured by adas-cog11 and adcs-adl at end of the treatment period in the overall cohort. the pre-specified subgroup of participants with p. gingivalis dna detectable in saliva at baseline (pg-ds; n=242) showed a dose response, with a 57% slowing of cognitive decline as measured by adas-cog11 in the 80 mg bid arm (p=0...
2021-07-23 08:00:00 - Press Release
Cortexyme Announces Lead 3clpro Inhibitor For The Treatment Of Coronavirus Infection
South san francisco, calif.--(business wire)---- $crtx--cortexyme, inc. (nasdaq: crtx), a company advancing a pivotal trial in alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3clpro inhibitor (cor803) for treatment of coronavirus infections, including covid-19 disease, caused by sars-cov-2 infection. “there continues to be a large unmet need for coronavirus treatment. the targ
2021-03-21 21:52:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Cortexyme, Inc. - Crtx
New york, new york--(newsfile corp. - march 21, 2021) - pomerantz llp is investigating claims on behalf of investors of cortexyme, inc. ("cortexyme" or the "company") (nasdaq: crtx). such investors are advised to contact robert s. willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.the investigation concerns whether cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [click here for information about joining the...
2021-03-18 20:01:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Cortexyme, Inc. - Crtx
New york, march 18, 2021 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of cortexyme, inc. ("cortexyme" or the "company") (nasdaq: crtx). such investors are advised to contact robert s.
2021-03-14 21:52:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Cortexyme, Inc. - Crtx
New york, new york--(newsfile corp. - march 14, 2021) - pomerantz llp is investigating claims on behalf of investors of cortexyme, inc. ("cortexyme" or the "company") (nasdaq: crtx). such investors are advised to contact robert s. willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.the investigation concerns whether cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [click here for information about joining the...
Latest News
2022-03-15 12:56:51 - InvestorPlace
Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today
Short-squeeze stocks continue to be a hot topic with retail traders and we're going over the top ones to keep an eye on for Tuesday! The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest Today appeared first on InvestorPlace.
2022-03-08 11:27:00 - Benzinga
Cortexyme Posts Safety Data From SAD Portion Of COR588 Trial In P.Gingivalis
Cortexyme Inc (NASDAQ: CRTX) has announced results from the single ascending dose (SAD) portion of the Phase 1 trial of COR588 for diseases related to P. gingivalis infection.
2022-02-28 21:15:15 - Seeking Alpha
Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment
COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases.
2022-02-18 11:39:40 - Zacks Investment Research
Here's Why Cortexyme, Inc. (CRTX) is Poised for a Turnaround After Losing 52% in 4 Weeks
Cortexyme, Inc. (CRTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2022-02-02 11:33:14 - Zacks Investment Research
After Plunging 47.5% in 4 Weeks, Here's Why the Trend Might Reverse for Cortexyme, Inc. (CRTX)
The heavy selling pressure might have exhausted for Cortexyme, Inc. (CRTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2022-02-01 11:36:36 - InvestorPlace
5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI
Short-squeeze stocks continue to be hot with traders and we're going over five candidates that investors will want to watch today. The post 5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI appeared first on InvestorPlace.
2022-01-26 15:21:48 - Schaeffers Research
Cortexyme Stock Sinks After FDA Puts Application on Hold
Cortexyme Inc (NASDAQ:CRTX) is plummeting today, last seen down 31.1% at $6.25, after the U.S. Food and Drug Administration (FDA) placed the company's application to start a study of its lead drug for Alzheimer's disease on hold.
2022-01-26 09:13:01 - Benzinga
Cortexyme Stock Plunges On FDA Hold On Atuzaginstat's IND
2022-01-12 10:00:00 - The Motley Fool
Why Cortexyme Stock Imploded in 2021
2022-01-07 15:21:09 - InvestorPlace
3 Most-Shorted Stocks at 52-Week Lows to Buy
In a market made up of stocks, these three most-shorted stocks look poised to deliver a much happier 2022 to bullish investors. The post 3 Most-Shorted Stocks at 52-Week Lows to Buy appeared first on InvestorPlace.